European Journal of Cancer
Volume 39, Issue 9 , Pages 1228-1233 , June 2003

Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

  • L. Mauriac

      Affiliations

    • Institut Bergonié, Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, 229, cours de l'Argonne, 33076 Bordeaux, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-5-5633-3333; fax: +33-5-5633-3385
    • ,
  • J.E. Pippen

      Affiliations

    • Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA
    • ,
  • J. Quaresma Albano

      Affiliations

    • Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal
    • ,
  • S.Z. Gertler

      Affiliations

    • Ottawa Regional Cancer Center, Ottawa, ON, Canada
    • ,
  • C.K. Osborne

      Affiliations

    • Breast Center at Baylor College of Medicine and Methodist Hospital, Houston, TX, USA

Received 6 September 2002 ,Revised 2 January 2003 ,Accepted 26 February 2003.

References 

  1. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer (twenty-eight years later). J. Clin. Oncol. 1995;13:513–529
  2. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In:  Harris JR editors. Diseases of the Breast, 2nd edn. Philadelphia: Lippincott Williams & Wilkins; 2000;p. 749–797 [chapter 48]
  3. Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role or aromatase inhibitors in the management of invasive carcinoma of the breast. J. Surg. Oncol. 2001;77:139–147
  4. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–3873
  5. Osborne CK, Jarman M, McCague R, et al.  The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother. Pharmacol. 1994;34:89–95
  6. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al.  Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 1995;87:746–750
  7. Howell A, Robertson JFR, Quaresma Albano J, et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002;20:3396–3403
  8. Osborne CK, Pippen J, Jones SE, et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy (results of a North American trial). J. Clin. Oncol. 2002;20:3386–3395
  9. Howell A, Osborne CK, Robertson JFR, et al. ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women—prospective combined analysis of two multicenter trials. Abstract presented at ECCO 2001, Lisbon, Portugal.
  10. Robertson JFR. A comparison of the single-dose pharmacokinetics of ICI 182,780 (‘Faslodex’) 250 mg when given as either a one × 5-ml intramuscular injection or two × 2.5-ml injections in postmenopausal women with advanced breast cancer. Breast Cancer Res. Treat. 2000;64:53; (abstr. 172)

PII: S0959-8049(03)00199-0

doi: 10.1016/S0959-8049(03)00199-0

European Journal of Cancer
Volume 39, Issue 9 , Pages 1228-1233 , June 2003

Article Tools

* Image Usage & Resolution